Alexion Pharmaceuticals Inc. (ALXN) and Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) Comparing side by side

This is a contrast between Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) based on their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alexion Pharmaceuticals Inc. 127 5.50 N/A 5.49 20.63
Kiniksa Pharmaceuticals Ltd. 16 0.00 N/A -3.03 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Alexion Pharmaceuticals Inc. and Kiniksa Pharmaceuticals Ltd.

Profitability

Table 2 demonstrates the return on assets, return on equity and net margins of Alexion Pharmaceuticals Inc. and Kiniksa Pharmaceuticals Ltd.

Net Margins Return on Equity Return on Assets
Alexion Pharmaceuticals Inc. 0.00% 14% 9.5%
Kiniksa Pharmaceuticals Ltd. 0.00% -49.1% -44.4%

Liquidity

Alexion Pharmaceuticals Inc. has a Current Ratio of 4 and a Quick Ratio of 3.6. Competitively, Kiniksa Pharmaceuticals Ltd.’s Current Ratio is 9.1 and has 9.1 Quick Ratio. Kiniksa Pharmaceuticals Ltd.’s better ability to pay short and long-term obligations than Alexion Pharmaceuticals Inc.

Analyst Ratings

Alexion Pharmaceuticals Inc. and Kiniksa Pharmaceuticals Ltd. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Alexion Pharmaceuticals Inc. 0 1 4 2.80
Kiniksa Pharmaceuticals Ltd. 0 0 1 3.00

The upside potential is 51.37% for Alexion Pharmaceuticals Inc. with consensus target price of $163.33. On the other hand, Kiniksa Pharmaceuticals Ltd.’s potential upside is 133.39% and its consensus target price is $26. Based on the results given earlier, Kiniksa Pharmaceuticals Ltd. is looking more favorable than Alexion Pharmaceuticals Inc., analysts view.

Institutional and Insider Ownership

The shares of both Alexion Pharmaceuticals Inc. and Kiniksa Pharmaceuticals Ltd. are owned by institutional investors at 98.8% and 85.5% respectively. Insiders owned roughly 0.3% of Alexion Pharmaceuticals Inc.’s shares. Competitively, Kiniksa Pharmaceuticals Ltd. has 0.1% of it’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Alexion Pharmaceuticals Inc. -6.35% -13.7% -15.54% -6.62% -13.85% 16.36%
Kiniksa Pharmaceuticals Ltd. -9.51% -11.61% -17.6% -35.38% -12.2% -57.99%

For the past year Alexion Pharmaceuticals Inc. had bullish trend while Kiniksa Pharmaceuticals Ltd. had bearish trend.

Summary

Alexion Pharmaceuticals Inc. beats on 7 of the 10 factors Kiniksa Pharmaceuticals Ltd.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. Further, it develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; SBC-103, which is in Phase I/II clinical trials for the treatment of metabolic disorders; ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; and ALXN 1210, which is in Phase I clinical trials to evaluate subcutaneous delivery. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; and Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for the development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.